Dolutegravir
Indication: HIV-1 infection
Population PK simulator for dolutegravir, an oral HIV integrase inhibitor used in combination antiretroviral therapy. Includes pregnancy and drug interaction effects relevant to HIV treatment exposure.
Drug Overview
Clinical Context
- Molecular Target
- HIV integrase
- Drug Class
- Integrase Strand Transfer Inhibitor (INSTI)
- Therapeutic Area
- HIV / Infectious Disease
- Indication
- HIV-1 infection
- Route of Administration
- Oral
Model Information
- Model Type
- Population PK
- Reference
- Liu et al. (2020) PBPK; Dooley et al. (2015) Br J Clin Pharmacol
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
Pharmacokinetic Parameters
PK Parameters
| Parameter | Value |
|---|---|
| ka | 2.24 h⁻¹ |
| CL F | 0.901 L/h |
| Vc F | 17.4 L |
Additional Parameters
| Parameter | Value |
|---|---|
| Cmax | ~3.67 µg/mL (50 mg QD, steady state) |
| dose | 50 mg QD or 50 mg BID |
Parameters sourced from published population pharmacokinetic models. Values represent typical population estimates; individual patient parameters may vary.
About This Simulator
This interactive pharmacokinetic simulator for Dolutegravir allows you to explore concentration-time profiles under different dosing scenarios. The underlying Population PK model characterizes the pharmacokinetics of this integrase strand transfer inhibitor (insti) following oral administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Dolutegravir PK simulator?
This is a free, interactive pharmacokinetic simulator for Dolutegravir used in HIV-1 infection. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Dolutegravir belong to?
Dolutegravir is classified as a Integrase Strand Transfer Inhibitor (INSTI) that targets HIV integrase. It is used in the HIV / Infectious Disease therapeutic area.
What route of administration does this model simulate?
This simulator models Oral administration of Dolutegravir. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a Population PK model. This model characterizes the time-course of drug concentrations following dosing.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
What is the half-life of Dolutegravir?
Based on the published model parameters, the elimination half-life of Dolutegravir is approximately ~14 h. Note that half-life can vary based on patient-specific factors such as body weight, organ function, and genetic polymorphisms.
What is the clearance of Dolutegravir?
The clearance (CL) of Dolutegravir is approximately 0.901 L/h. Clearance represents the volume of plasma from which drug is completely removed per unit time and is a key determinant of drug exposure and steady-state concentrations.
Ready to Simulate?
Launch the Dolutegravir simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community